Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia.
To determine the role of CD14 in lipopolysaccharide (LPS)-induced release of chemokines, 16 humans were injected with LPS (4 ng/kg) preceded (-2 h) by intravenous IC14, an anti-human CD14 monoclonal antibody, or placebo. LPS elicited increases in interleukin (IL)-8 concentrations in plasma and in lysates of red blood cell (RBC), polymorphonuclear cell and mononuclear cell fractions, which were all reduced by IC14. LPS also induced rises in the plasma and RBC levels of monocyte chemoattractant protein (MCP)-1, which were diminished by IC14. Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, chemokines that in contrast to IL-8 and MCP-1 can not bind to the Duffy antigen receptor for chemokines on RBCs, were only detected in plasma. IC14 attenuated the LPS-induced release of MIP-1beta, but not of MIP-1alpha. IL-8 and MCP-1, but not MIP-1alpha and MIP-1b, circulate in RBC-associated form during endotoxemia. LPS-induced chemokine release is, in part, mediated by an interaction with CD14.
Olszyna
Dariusz P
DP
Department of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Verbon
Annelies
A
Pribble
John P
JP
Turner
Terence
T
Axtelle
Tim
T
van Deventer
Sander J H
SJ
van der Poll
Tom
T
D000328:Adult; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D018925:Chemokines / Q000097:blood*; D004311:Double-Blind Method; D019446:Endotoxemia / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000276:immunology*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D010919:Placebos; D012016:Reference Values
D000941:Antigens; D018925:Chemokines; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D010919:Placebos